Trevi Therapeutics Inc (TRVI) - Total Assets
Based on the latest financial reports, Trevi Therapeutics Inc (TRVI) holds total assets worth $179.61 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Trevi Therapeutics Inc to assess how comfortably operating cash covers total debt obligations.
Trevi Therapeutics Inc - Total Assets Trend (2016–2025)
This chart illustrates how Trevi Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See TRVI total equity for net asset value and shareholders' equity analysis.
Trevi Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Trevi Therapeutics Inc's total assets of $179.61 Million consist of 99.1% current assets and 0.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.8% |
| Accounts Receivable | $986.00K | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Trevi Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see TRVI stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Trevi Therapeutics Inc's current assets represent 99.1% of total assets in 2025, a decrease from 99.8% in 2016.
- Cash Position: Cash and equivalents constituted 9.8% of total assets in 2025, down from 98.5% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Trevi Therapeutics Inc Competitors by Total Assets
Key competitors of Trevi Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
SL Science Holding Limited Ordinary Shares
NASDAQ:SLBT
|
USA | $2.82 Million |
|
REMEGEN CO. LTD YC 1
F:REG
|
Germany | €7.25 Billion |
Trevi Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 24.75 | 15.38 | 4.09 |
| Quick Ratio | 24.75 | 15.38 | 4.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $169.01 Million | $98.75 Million | $29.07 Million |
Trevi Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Trevi Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 14.79 |
| Latest Market Cap to Assets Ratio | 12.31 |
| Asset Growth Rate (YoY) | 74.4% |
| Total Assets | $193.44 Million |
| Market Capitalization | $2.38 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Trevi Therapeutics Inc's assets at a significant premium (12.31x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Trevi Therapeutics Inc's assets grew by 74.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Trevi Therapeutics Inc (2016–2025)
The table below shows the annual total assets of Trevi Therapeutics Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $193.44 Million | +74.43% |
| 2024-12-31 | $110.90 Million | +24.05% |
| 2023-12-31 | $89.40 Million | -27.32% |
| 2022-12-31 | $123.02 Million | +219.73% |
| 2021-12-31 | $38.48 Million | -18.37% |
| 2020-12-31 | $47.13 Million | -21.45% |
| 2019-12-31 | $60.00 Million | +192.84% |
| 2018-12-31 | $20.49 Million | -7.82% |
| 2017-12-31 | $22.23 Million | +164.34% |
| 2016-12-31 | $8.41 Million | -- |
About Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction i… Read more